Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $293,450.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the sale, the director now owns 33,611 shares of the company’s stock, valued at $1,972,629.59. This trade represents a 12.95 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00.
• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00.

Halozyme Therapeutics Trading Up 2.4 %

HALO opened at $59.53 on Thursday. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm has a market capitalization of $7.33 billion, a price-to-earnings ratio of 17.36, a PEG ratio of 0.42 and a beta of 1.25. The company’s 50 day moving average price is $54.96 and its two-hundred day moving average price is $54.71.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

HALO has been the topic of several recent analyst reports. Benchmark reissued a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Wells Fargo & Company decreased their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, HC Wainwright lifted their price target on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Heck Capital Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the 4th quarter worth approximately $29,000. CBIZ Investment Advisory Services LLC acquired a new position in shares of Halozyme Therapeutics in the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC lifted its position in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics in the 4th quarter worth approximately $69,000. Finally, Parkside Financial Bank & Trust lifted its position in shares of Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 322 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.